These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 3814034)
21. Control of simulator sickness in an AH-64 aviator. Kroll JD Aviat Space Environ Med; 1989 Dec; 60(12):1202-3. PubMed ID: 2604677 [TBL] [Abstract][Full Text] [Related]
22. Effects of transcutaneous scopolamine and depth on diver performance. Williams TH; Wilkinson AR; Davis FM; Frampton CM Undersea Biomed Res; 1988 Mar; 15(2):89-98. PubMed ID: 3363755 [TBL] [Abstract][Full Text] [Related]
23. [Scopolamine plaster caused hallucination. Toxic psychosis in a 10-year-old boy caused by an agent against motion sickness]. Björk M; Wettergren B Lakartidningen; 1995 Feb; 92(7):638. PubMed ID: 7861858 [No Abstract] [Full Text] [Related]
24. Transdermal scopolamine: human performance and side effects. Gordon C; Binah O; Attias J; Rolnick A Aviat Space Environ Med; 1986 Mar; 57(3):236-40. PubMed ID: 3964152 [TBL] [Abstract][Full Text] [Related]
25. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Graybiel A; Cramer DB; Wood CD Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807 [TBL] [Abstract][Full Text] [Related]
26. INM investigations into drugs for seasickness prophylaxis. Pingree BJ J R Nav Med Serv; 1994; 80(2):76-80. PubMed ID: 7707278 [TBL] [Abstract][Full Text] [Related]
27. The effect of antimotion sickness drugs on habituation to motion. Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377 [TBL] [Abstract][Full Text] [Related]
28. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Nachum Z; Shupak A; Gordon CR Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539 [TBL] [Abstract][Full Text] [Related]
29. Effect of cinnarizine in the prevention of seasickness. Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A Aviat Space Environ Med; 1994 Jul; 65(7):606-9. PubMed ID: 7945126 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of betahistine for the prevention of seasickness: effect on vestibular function, psychomotor performance and efficacy at sea. Gordon CR; Doweck I; Nachum Z; Gonen A; Spitzer O; Shupak A J Vestib Res; 2003; 13(2-3):103-11. PubMed ID: 14757913 [TBL] [Abstract][Full Text] [Related]
31. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness. Wang ET; Zhou DR; He LH Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432 [TBL] [Abstract][Full Text] [Related]
33. Effects of scopolamine on autonomic profiles underlying motion sickness susceptibility. Uijtdehaage SH; Stern RM; Koch KL Aviat Space Environ Med; 1993 Jan; 64(1):1-8. PubMed ID: 8424733 [TBL] [Abstract][Full Text] [Related]
34. Seasickness in totally-enclosed motor-propelled survival craft: remedial measures. Landolt JP; Monaco C Aviat Space Environ Med; 1992 Mar; 63(3):219-25. PubMed ID: 1567325 [TBL] [Abstract][Full Text] [Related]
35. I heard that the adhesive patch you can wear to prevent motion sickness is available again. Why was it taken off the market? Mayo Clin Health Lett; 1998 Mar; 16(3):8. PubMed ID: 9516375 [No Abstract] [Full Text] [Related]
36. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action]. Wang E Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342 [TBL] [Abstract][Full Text] [Related]